Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077580 | 0.84 | ANPEP (0.59) | ALDH1A1SLC7A5ANPEPENPEPCA12 | |
| SCHEMBL9367897 | 0.83 | SLC7A5 (0.53) | ALDH1A1MAPTALPIPKMPTGS1 | |
| SCHEMBL2639450 | 0.82 | EPHX1 (0.56) | MEN1KMT2AALPIPKMPTGS1 | |
| SCHEMBL623688 | 0.82 | EPHX1 (0.56) | MEN1KMT2AALPIPKMPTGS1 | |
| SCHEMBL6486058 | 0.82 | EPHX1 (0.56) | MEN1KMT2AALPIPKMPTGS1 | |
| SCHEMBL7327748 | 0.82 | EPHX1 (0.56) | MEN1KMT2AALPIPKMPTGS1 | |
| SCHEMBL309963 | 0.82 | EPHX1 (0.56) | MEN1KMT2AALPIPKMPTGS1 | |
| SCHEMBL24311844 | 0.80 | SRR (0.50) | LMNAALPIPKMPTGS1XIAP | |
| SCHEMBL13962960 | 0.80 | SRR (0.50) | LMNAALPIPKMPTGS1XIAP | |
| SCHEMBL18647219 | 0.80 | SRR (0.50) | LMNAALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017044633-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20100112089-A1 | PEPTIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-06 | — | — | US | disclosed |
| WO-2009139497-A1 | CBP501 -DERIVED AGENTS AND METHODS BASED THEREON FOR INHIBITING G2 CELL CYCLE ARREST AND SENSITIZING CELLS TO DNA DAMAGING AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | WO | disclosed |
| US-20060030518-A1 | Acylated insulin | SCIAPS, INC. | 2006-02-09 | — | — | US | disclosed |
| US-6869930-B1 | Acylated insulin | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030518-A1 | Acylated insulin | INSR, BCAT1, SLC1A5 | ALDH1A1 3689/4885CAPN1 1966/4885SRD5A2 2178/4885 |
| US-20100112089-A1 | PEPTIDE COMPOUND AND USE THEREOF | HDAC10, NGLY1, VIP | ALDH1A1 3911/4885CAPN1 185/4885SRD5A2 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.